A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination with CApecitabine for Subjects with Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (the RECAP trial)

Grants and Contracts Details

StatusFinished
Effective start/end date4/24/126/30/14

Funding

  • Medpace Inc: $28,895.00